http://eu-acgt.org/ Latest News en http://eu-acgt.org/ http://eu-acgt.org/ Latest News TYPO3 - get.content.right http://blogs.law.harvard.edu/tech/rss Fri, 05 Mar 2010 15:26:00 +0100 VPH 2010: the registration and the call for abstracts are open! http://eu-acgt.org/no_cache/news/news-single/article/vph-2010-the-registration-and-the-call-for-abstracts-are-open-1.html Brussels, Belgium, 30th September to 1st October, 2010 The meeting on 30th September - 1st October will be dedicated to the VPH Initiative, bringing together key representatives from VPH groups, Industry and Clinics. The first meeting is designed to be a relatively small meeting up to a maximum of 200 participants with high profile key speakers and will contain the very best of VPH research. Parallel sessions will be held on both days with proposed topics in four main themes; Organ Systems, Modelling Scales, Research Methodology, Application Domains and Data Access and Information Assurance. We anticipate increasing the size and scope of the VPH conference in subsequent years.

 

KEY DATES

Early Bird Registration of Euro 280 by 31st July!

Deadline for abstract submission: 1st May 2010

Authors Notifications: 30th June 2010

KEYNOTE SPEAKERS

Professor Aleksander Popel, Johns Hopkins University

Professor Nadia Rosenthal, European Molecular Biology Laboratory Monterotondo

Professor Norbert Graf, University Hospital of the Saarland

Professor Janet Thornton, European Bioinformatics Institute, Cambridge

 

CALL FOR ABSTRACTS

Submissions for posters or for oral presentations are welcome. Both kinds of submissions will be subject to the same reviewing process. Contributors are asked to submit abstracts rather than full papers. Submitted abstracts will be selected for inclusion in VPH 2010 by the VPH 2010 Programme Committee for:

  • Inclusion as an oral presentation and Invitation to submit a full paper for possible inclusion in the Interface Focus Issue
  • Inclusion as an oral presentation and/or
  • Inclusion as a poster or
  • Not suitable for inclusion

Talks and posters will appear in electronic format on the conference web pages via the VPH NoE website.

The submission should be no more than 2 A4 pages of text (1800 words) or up to three pages if it includes diagrams, tables and references, with the extra space devoted to these and any captions. Font size should be no smaller than 10 pt Times New Roman with 2.5cm margins. All pages should be numbered and diagrams and tables should be positioned in their proper place in relation to the text, ensuring that the total contribution does not exceed 3 pages. Authors invited to prepare full manuscripts for submission to Interface Focus will also need to adhere to a further schedule for submission and review; final copy will be required by 15th February 2011.

 

CONFERENCE THEMES

Contributions are invited in, but not limited to, the following areas and topics:

Organ Systems

  • Neuromusculoskeletal
  • Cardiovascular
  • Lymphatic and immunological
  • Dermatological
  • Respiratory
  • Endocrine-metabolic
  • Other

Modelling Scales

  • Population-organism modelling
  • Organism-organ modelling
  • Organ-tissue modelling
  • Tissue-cell modelling
  • Cell-molecule modelling

Research Methodology

  • Data management
  • Numerical methods and modelling tools
  • Experimental methods for models validation
  • Probabilistic and adaptive methods
  • ICT for integrative modelling
  • Multiscale visualisation and data processing

Application Domains

  • Systems physiology research
  • Systems Biology research
  • Screening, monitoring and diagnosis
  • Pharmacology and drug development
  • Medical devices design and testing
  • Model assisted planning and treatment
  • Mechanisms and models of disease

Data Access & Information Assurance

  • Ethics/Data privacy and security
  • Intellectual property rights
  • Accessing and sharing of medical data: technical, personal, legal and policy perspective

The possibility of a space for exhibits and demonstrators is anticipated. If you would be interested in representing your project, organisation or company at this conference at a booth then please contact the conference organisers.

Please refer to the conference website for further details and instructions. If you have any questions regarding abstract submission or registration please contact the VPH2010 Conference Team at vph2010@ercim.eu

]]> News nathanael.verhaeghe@healthgrid.org Fri, 05 Mar 2010 15:26:00 +0100 The ACGT Competition is open! http://eu-acgt.org/no_cache/news/news-single/article/the-acgt-competition-is-open.html The ACGT Competition has been set up to encourage the development of Grid enabled services that can... The ACGT Competition has been set up to encourage the development of Grid enabled services that can be used for the support of multi-centric clinical trials and research. The ACGT Competition is open to all parties that are interested in developing ACGT-compatible services.  The competition will take place between March and June 2010.

 

The important dates are: 

  • 30th March, 2010, 5pm CET: Deadline for registering your entry
  • 30th May, 2010, 5pm CET: Deadline for submitting your entry
  • 1st June - 15th June, 2010: Judging Process
  • 20th June 2010: Announcement of winning entries
  • Award Ceremony: Date to be announced

For further details about the competition, please visit the ACGT Competition Wiki

 

]]> home nathanael.verhaeghe@healthgrid.org Tue, 23 Feb 2010 16:00:00 +0100 Release of the ACGT article on Wikipedia http://eu-acgt.org/no_cache/news/news-single/article/release-of-the-acgt-article-on-wikipedia.html A description of the ACGT project is now available on the largest encyclopedia: Wikipedia. For... A description of the ACGT project is now available on the largest encyclopedia: Wikipedia.

For further details, read the article. 

]]> home nathanael.verhaeghe@healthgrid.org Thu, 04 Feb 2010 10:28:00 +0100 FDA expands use of breast cancer drug Tykerb http://eu-acgt.org/no_cache/news/news-single/article/fda-expands-use-of-breast-cancer-drug-tykerb.html The U.S. Food and Drug Administration today approved Tykerb (lapatinib) in combination with Femara... The U.S. Food and Drug Administration today approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated.

Tykerb a breast cancer drug made by GlaxoSmithKine while Femara is another breast cancer drug made by Novartis. Tykerb cuts communication between tumor cells and block functions of the HER2 protein in a way the cancer growth can be slowed. In combination with Femara, treated patients doubled the time they lived without the cancer progressing.

For further details, read the FDA press release published January 29th, 2010.

]]> home nathanael.verhaeghe@healthgrid.org Tue, 02 Feb 2010 15:55:00 +0100 Biovista Inc. and FDA to Collaborate on a Medication Safety Initiative http://eu-acgt.org/no_cache/news/news-single/article/biovista-inc-and-fda-to-collaborate-on-a-medication-safety-initiative.html Biovista Inc. today announced that the U.S. Food and Drug Administration (FDA) has licensed its... Biovista Inc. today announced that the U.S. Food and Drug Administration (FDA) has licensed its technology platform to help analyze, identify, and better understand the way certain drugs can cause harmful side effects.

For further informations, read the PR Newwire Press Release

]]> home News nathanael.verhaeghe@healthgrid.org Thu, 14 Jan 2010 09:50:00 +0100